Gland Pharma Q2 FY26 – ₹ 14,869 mn revenue (₹ 1,486.9 cr) & ₹ 1,837 mn PAT (₹ 183.7 cr): Injecting Growth One Vial at a Time
1. At a Glance
Hyderabad’s own Gland Pharma Ltd just reported its Q2 FY26 results and, let’s be honest, the numbers look cleaner than a freshly sterilised syringe. The company clocked ₹ 14,869 million (₹ 1,486.9 crore) in revenue and ₹ 1,837 million (₹ 183.7 crore) in PAT, up 6 % YoY and 12 % YoY respectively. EBITDA stood at ₹ 3,140 million (₹ 314 crore), giving an OPM of ~21 %.
At a market cap of ₹ 32,480 crore, price ₹ 1,972, and P/E ≈ 41×, it isn’t cheap. But when you’re debt-light (Debt-to-Equity 0.03×), high on approvals, and busy charming the US FDA, you get to demand premium multiples.
Return in the last 6 months? +40 %. Return over 3 months? Barely +0.4 %. Clearly, this syringe injects profits slowly but steadily.
2. Introduction
Founded in 1978 in Hyderabad, Gland Pharma went from being a humble contract filler of small-volume liquid parenterals to a global powerhouse shipping sterile injectables to 60 countries. Now promoted by Shanghai Fosun Pharma, it runs on a B2B model (98 % of FY24 revenue), making other pharma brands look good while quietly printing cash behind the curtains.
Between FY22 and FY24, revenue jumped 29 %, aided by new molecules and the Cenexi acquisition in France and Belgium. Margins, though, slipped from 34 % to 24 %—because European engineers apparently don’t come cheap.
Yet, in an industry where regulatory inspections cause heart attacks, Gland keeps walking out of US FDA facilities with “minor observations” instead of “major violations.”
And just as analysts were dozing off, the company signed a biologics CDMO term sheet with Dr Reddy’s Labs. Two Hyderabad giants teaming up—what could possibly go wrong?
3. Business Model – WTF Do They Even Do?
Simple story, complex science. Gland Pharma develops and manufactures sterile injectable formulations—vials, ampoules, pre-filled syringes, lyophilized vials, infusions, oncology and ophthalmic products—for global clients under contract.
Model Split (FY24):
B2B 98 % (vs 95 % in FY22) – contract development and manufacturing for multinationals.
B2C 2 % (vs 5 % in FY22) – direct sales in India to ~4,000 hospitals and government institutions.
Geographical Mix (H1 FY25): US 54 %, Europe 18 %, India 5 %, RoW 20 %. Europe’s jump (from 5 % to 18 %) is pure Cenexi.
It runs four Indian formulation plants, three API sites, and through Cenexi, four European plants—an injectable octopus with sterile arms everywhere.
4. Financials Overview
Quarterly figures in ₹ million (per company announcement) (₹ 14,869 mn = ₹ 1,486.9 cr for reference)
